Sandler Capital Management’s Quest Diagnostics DGX Stock Holding History

Sandler Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.73M	Sell	12,889 -2,066	-14%	-$405K	1.36%	19
2026 Q1	$2.93M	Buy	+14,955	New	+$2.91M	1.52%	13
2025 Q2	–	Sell	-19,993	Closed	-$3.38M	–	156
2025 Q1	$3.38M	Buy	+19,993	New	+$3.28M	0.85%	50
2021 Q2	–	Sell	-85,000	Closed	-$10.9M	–	108
2021 Q1	$10.9M	Buy	85,000 +28,100	+49%	+$3.46M	0.93%	43
2020 Q4	$6.78M	Buy	+56,900	New	+$6.94M	0.79%	53
2020 Q2	–	Sell	-91,200	Closed	-$7.32M	–	88
2020 Q1	$7.32M	Buy	+91,200	New	+$9.44M	1.01%	42
2018 Q2	–	Sell	-62,000	Closed	-$6.22M	–	115
2018 Q1	$6.22M	Buy	+62,000	New	+$6.35M	0.76%	57
2017 Q2	–	Sell	-85,360	Closed	-$8.38M	–	149
2017 Q1	$8.38M	Buy	+85,360	New	+$8.14M	0.58%	66
2015 Q2	–	Sell	-96,730	Closed	-$7.43M	–	187
2015 Q1	$7.43M	Buy	96,730 +6,330	+7%	+$453K	0.46%	84
2014 Q4	$6.06M	Buy	+90,400	New	+$5.7M	0.32%	120

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Sandler Capital Management's DGX Position: Q2 2026 in Review

Sandler Capital Management reduced its Quest Diagnostics (DGX) stake by 14% in Q2 2026, selling an estimated $405K and leaving 12,889 shares worth $2.73M. The position accounts for 1.36% of the portfolio, ranked #19.

Sandler Capital Management first reported a position in DGX in Q4 2014 and has held it in 10 quarters since. The position peaked at $10.9M in Q1 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Sandler Capital Management held 12,889 shares of Quest Diagnostics worth $2.73M as of Q2 2026.
Sandler Capital Management sold 2,066 Quest Diagnostics shares in Q2 2026, an estimated $405K.
Quest Diagnostics made up 1.36% of Sandler Capital Management's portfolio in Q2 2026, its #19 holding.
Sandler Capital Management first reported a position in Quest Diagnostics in Q4 2014 and has held it in 10 quarters since.
Sandler Capital Management's Quest Diagnostics position peaked at $10.9M in Q1 2021.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Sandler Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.